Disorders of MicroRNAs in Peripheral Blood Mononuclear Cells: As Novel Biomarkers of Ankylosing Spondylitis and Provocative Therapeutic Targets
Table 2
Expression level of microRNAs in both AS and control group validated by real-time PCR.
microRNA
AS group/control group (interval)
AS group before/after therapy (interval)
hsa-miR-202
1.28 (0.28~5.88)
0.50 (0.13~2.08)
hsa-miR-21
0.51 (0.11~2.5)
—
hsa-miR-26b**
0.70 (0.26~1.89)
3.43 (1.20~9.85)
hsa-miR-27a*
0.07 (0.01~0.58)
0.8 (0.27~2.43)
hsa-miR-29a**
0.26 (0.12~0.53)
0.35 (0.25~1.24)
hsa-miR-29b**
1.22 (0.67~2.22)
0.43 (0.19~0.97)
hsa-miR-494**
0.58 (0.52–5.6)
0.21 (0.05~0.89)
hsa-miR-526a**
1.20 (0.48~3.03)
0.40 (0.13~1.14)
hsa-miR-98*
0.44 (0.10~1.89)
—
hsa-miR-let7a
0.91 (0.16~4.76)
—
hsa-miR-let7f
0.54 (0.11~2.70)
—
hsa-miR-let7i*,**
0.27 (0.05~1.49)
0.27 (0.05~1.47)
hsa-miR-126-3p*
0.15 (0.03~0.75)
0.51 (0.28~0.93)
MicroRNAs had statistically significantly different expression in AS group and healthy control group (fold changes >2, < 0.05). **Expression levels were changed statistically significantly after medicine treatment (fold changes >2, < 0.05).
